Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Abstract : BACKGROUND: Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. METHODS AND RESULTS: In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.64-1.80; absolute risk difference, 0.2%; 95% CI, -1.0 to 1.3; P<0.001 for the prespecified noninferiority margin for both criteria). The safety end point, major bleeding, occurred in 15 patients receiving dabigatran (1.2%) and in 22 receiving warfarin (1.7%; hazard ratio, 0.69; 95% CI, 0.36-1.32). Any bleeding occurred in 200 dabigatran (15.6%) and 285 warfarin (22.1%; hazard ratio, 0.67; 95% CI, 0.56-0.81) patients. Deaths, adverse events, and acute coronary syndromes were similar in both groups. Pooled analysis of this study RE-COVER II and the RE-COVER trial gave hazard ratios for recurrent VTE of 1.09 (95% CI, 0.76-1.57), for major bleeding of 0.73 (95% CI, 0.48-1.11), and for any bleeding of 0.70 (95% CI, 0.61-0.79). CONCLUSION: Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE. CLINICAL TRIAL REGISTRATION URL: Unique identifiers: NCT00680186 and NCT00291330.
Type de document :
Article dans une revue
Circulation, American Heart Association, 2014, 129 (7), pp.764-72. 〈10.1161/CIRCULATIONAHA.113.004450〉
Liste complète des métadonnées
Contributeur : Ghislaine Calvez <>
Soumis le : mardi 22 juillet 2014 - 15:56:20
Dernière modification le : dimanche 15 octobre 2017 - 22:44:04

Lien texte intégral




Sam Schulman, Ajay K Kakkar, Samuel Z Goldhaber, Sebastian Schellong, Henry Eriksson, et al.. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.. Circulation, American Heart Association, 2014, 129 (7), pp.764-72. 〈10.1161/CIRCULATIONAHA.113.004450〉. 〈hal-01030866〉



Consultations de la notice